Form 4: VolitionRx GC Vests 44,700 Shares from RSU Grant

VolitionRx's General Counsel, Nicholas Plummer, vested 44,700 restricted stock units, adding to his direct beneficial ownership.

Summary

• Nicholas Plummer, General Counsel of VolitionRx Ltd. (VNRX), reported the vesting of 44,700 restricted stock units (RSUs) on January 22, 2026.
• These RSUs originated from an award of 149,000 RSUs granted on March 17, 2025, under the company's 2024 Stock Incentive Plan.
• The vesting of the 44,700 RSUs occurred because certain corporate performance goals were met.
• The 44,700 vested RSUs are subject to a 3-year time-based vesting schedule, with 14,900 units scheduled to vest on March 17, 2026, March 17, 2027, and March 17, 2028, respectively.
• Upon each time-based vesting and settlement, Plummer will receive shares of common stock equal to the number of units that have vested.
• The remaining 104,300 RSUs from the original grant did not vest due to unmet performance goals and were cancelled on June 30, 2025, and January 22, 2026.
• Following this transaction, Plummer's direct beneficial ownership of VolitionRx common stock stands at 238,784 shares.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The vesting of RSUs is a positive for the executive and indicates some performance goals were met, but the cancellation of a larger portion of the original grant due to unmet goals introduces a slight negative aspect.

Positives

• The vesting of 44,700 restricted stock units indicates the achievement of certain corporate performance goals by VolitionRx.
• The transaction increases the General Counsel's direct beneficial ownership, further aligning management's interests with those of shareholders.

Negatives

• A significant portion of the original RSU grant, specifically 104,300 units, did not vest and was cancelled due to unmet performance goals.

Risks

• Failure to meet all corporate performance goals resulted in the cancellation of 104,300 restricted stock units, indicating potential challenges in achieving all set objectives.

Future Outlook

The vesting schedule for the 44,700 RSUs extends through March 2028, indicating future share issuances to the General Counsel upon the fulfillment of time-based vesting conditions.

Management Comments

• Nicholas Plummer, General Counsel, reported the vesting of 44,700 restricted stock units, reflecting the achievement of certain corporate performance goals.

Industry Context

This transaction is a routine insider filing for executive compensation, common across industries where restricted stock units are used to incentivize management and align their interests with long-term company performance.

Comparison to Industry Standards

• NA This Form 4 reports an individual insider transaction (RSU vesting) and does not provide company-wide performance data for industry comparison.

Stakeholder Impact

• Shareholders: Increased alignment of management's interests with shareholders through direct stock ownership.
• Employees: Reflects the company's compensation structure for executives, potentially influencing employee incentive programs.

Next Steps

• Future vesting of 14,900 units of common stock on March 17, 2026, March 17, 2027, and March 17, 2028, respectively, from the currently vested RSUs.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of restricted stock units for an executive. While it indicates some corporate performance goals were met, a significant portion of the original grant was cancelled. This type of filing typically does not provide sufficient information to warrant a change in investment recommendation, thus a 'hold' stance is maintained, pending more comprehensive financial or operational updates.

Keywords

VolitionRx, VNRX, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Nicholas Plummer, Stock Incentive Plan